



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

KOR/DOR agonist 1

Cat. No.:	HY-162552
Molecular Formula:	C ₂₈ H ₃₂ N ₂ O ₅
Molecular Weight:	476.56
Target:	Opioid Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	KOR/DOR agonist 2 is a KOR and DOR opioid receptors agonist with K _i values of 0.14 nM, and 0.93 nM, respectively. KOR/DOR agonist 2 shows significant antinociceptive effects. KOR/DOR agonist 2 penetrates the blood-brain barrier ^[1] .		
IC₅₀ & Target	κ Opioid Receptor/KOR 0.14 nM (K _i)	δ Opioid Receptor/DOR 0.2 nM (K _i)	μ Opioid Receptor/MOR 0.93 nM (K _i)
In Vitro	KOR/DOR agonist 2 (compound 21) has subnanomolar binding for the MOR, with a K _i of 0.20 nM ^[1] . In [35S]-GTPγS-binding assay, KOR/DOR agonist 2 shows functional activity at the KOR, MOR, and DOR with an EC ₅₀ values of 0.04 nM, 0.58 nM, 1.28 nM, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	KOR/DOR agonist 2 (0.1 mg/kg; subcutaneous injection; once) results in significant antinociceptive effects in a warm-water tail immersion assay ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	Male Swiss Webster mice (6-8 week-old) ^[1]	
	Dosage:	0.1 mg/kg	
	Administration:	Subcutaneous injection; once	
	Result:	Showed significant antinociceptive effects.	

REFERENCES

[1]. Celsey M St Onge, et al. Systematic Structure-Activity Relationship Study of Nalfurafine Analogues toward Development of Potentially Nonaddictive Pain Management Treatments. J Med Chem. 2024 May 30.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA